Atrogi participated in BIO-Europe 2017 in Berlin, which is the largest partnering meeting in Europe. The purpose was to present our type 2 diabetes project to pharmaceutical companies. At the meeting Atrogi met with several of the largest companies that are working in the diabetes area. The response was overwhelming and Atrogi will follow up the requests for information.
One of Atrogis patent application was granted in the US (US 9,784,726). The patent describes inventions useful for finding compounds for the treatment of diseases such as type 2 diabetes. This was the second time such a patent was granted.
Atrogi was awarded a 5 MSEK grant. This very prestigeful grant from the SWElifes accelerator program was received in fierce competition with other applicants. The grant will be used to help bring one of the compounds that Atrogis is developing for the treatment of type 2 diabetes to the clinic.
